Tarsus Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tarsus Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 88% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-9.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 51% of Healthcare companies in United States.
Cash Locked Ratio
$14For every $100 of sales, $14 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $7 from others' credit three years earlier.
Less money tied up than 70% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$1Sales grew 1,648% in 3 years, but profit fell: $1 less profit per $100 of extra sales.
Lower than 69% of Healthcare companies in United States.
Asset Productivity Ratio
+1648% / +147%In 3 years sales changed by +1648% while total assets changed by +147%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+10%Cash, after subtracting all debt, equals 10% of its market value (net cash).
Higher than 51% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 87% of Healthcare companies in United States.
Tangible Net Worth Ratio
98%Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 88% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Tarsus Pharmaceuticals, Inc. made a loss over the last year. Tarsus Pharmaceuticals, Inc. owes $0.43 for every $1 it owns. Tarsus Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTarsus Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
9.73The share price is 9.73 times Tarsus Pharmaceuticals, Inc.'s book value per share, higher than 86% of Healthcare companies in United States.
Market cap
$3.4 BThe total market value of all of Tarsus Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 81% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$347 MWhat Tarsus Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.41Net worth divided by the number of shares. The share price of $72.08 is 9.7 times this, which is the P/B above.
Return on equity (ROE)
-13.7%Tarsus Pharmaceuticals, Inc. lost 13.7% of its shareholders' money over the last year, higher than 69% of Healthcare companies in United States.
Owes vs Owns
0.43×Tarsus Pharmaceuticals, Inc. owes $0.43 for every $1 it owns (low), higher than 51% of Healthcare companies in United States.
Dividend yield
NoneTarsus Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+147%Revenue rose 147% in the year to Dec 2025, and grew 160% a year on average over 3 years.
Profit growth
LossTarsus Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-14.7%Tarsus Pharmaceuticals, Inc. lost $15 for every $100 of revenue.
Interest cover
Not coveredTarsus Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashTarsus Pharmaceuticals, Inc. held $345 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Tarsus Pharmaceuticals, Inc.: $3.4 B ÷ $347 M (30 Jun 2026) = 9.7.
What is Tarsus Pharmaceuticals, Inc.'s return on equity?
Tarsus Pharmaceuticals, Inc. lost 13.7% of its shareholders' money over the last year, higher than 69% of Healthcare companies in United States.
How much does Tarsus Pharmaceuticals, Inc. owe compared with what it owns?
Tarsus Pharmaceuticals, Inc. owes $0.43 for every $1 it owns (low), higher than 51% of Healthcare companies in United States.
Does Tarsus Pharmaceuticals, Inc. pay a dividend?
No. Tarsus Pharmaceuticals, Inc. does not currently pay a dividend.
Is Tarsus Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 147% in the year to Dec 2025, and grew 160% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.